AstraZeneca PLC (AZN)vsPrecision BioSciences Inc (DTIL)
AZN
AstraZeneca PLC
$189.62
-3.04%
HEALTHCARE · Cap: $284.30B
DTIL
Precision BioSciences Inc
$7.88
+1.40%
HEALTHCARE · Cap: $204.35M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 133991% more annual revenue ($60.44B vs $45.07M). AZN leads profitability with a 17.2% profit margin vs -96.7%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
DTIL
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$189.62
$4.95 discount
Margin of Safety
+72.2%
Fair Value
$14.65
Current Price
$7.88
$6.77 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 37272.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth, Price/Book. Revenue growth of 37272.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while DTIL is a hypergrowth play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.28 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 33/100), backed by strong 17.2% margins and 12.5% revenue growth. DTIL offers better value entry with a 72.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?